Mobic (Meloxicam)

Meloxicam works by reversibly inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, with a greater effect on COX‑2. This reduces the synthesis of prostaglandins, which are chemicals that promote inflammation, pain, and fever, thereby providing analgesic and anti‑inflammatory benefits.

The dosage of Mobic is determined by the prescribing clinician based on the patient’s condition, severity of symptoms, and overall health status. Healthcare professionals follow approved prescribing information and adjust the dose as needed for each individual.

Meloxicam, like other NSAIDs, is generally not recommended during pregnancy, especially in the third trimester, and should be used with caution while breastfeeding. Patients should discuss potential risks and alternatives with their healthcare provider.

To order Mobic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Mobic (meloxicam) offers a longer half‑life and preferential COX‑2 inhibition compared with many traditional NSAIDs, which may allow once‑daily dosing and potentially lower gastrointestinal risk. However, individual response varies, and clinicians consider patient history, comorbidities and drug‑interaction profiles when selecting an NSAID.

Mobic injectable should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use and discard any solution that appears discolored or contains particles.

Mobic is supplied as an injectable solution intended for intramuscular injection. A qualified healthcare professional administers the dose into a suitable muscle, typically the gluteal or deltoid region, following aseptic technique and the prescribing information.

Serious risks include gastrointestinal ulceration or bleeding, cardiovascular events such as myocardial infarction or stroke, severe skin reactions like Stevens‑Johnson syndrome, and renal or hepatic impairment. Patients should be monitored for signs of these conditions and seek immediate medical attention if they occur.

Mobic should be avoided in patients with known hypersensitivity to meloxicam or other NSAIDs, those with active gastrointestinal bleeding, severe renal or hepatic failure, and individuals with a history of cardiovascular thrombotic events unless specifically directed by a physician.